Biocancell Ltd., of Jerusalem, said that a full tender offer for its shares that was published by a group of investors led by its largest shareholder, Clal Biotechnology Industries Ltd. earlier this month, was not approved by shareholders, with the shareholder acceptance rate falling below the minimum required acceptance rate needed.